NAMSA has acquired select assets of Labcorp’s early development medical device testing business.
The business acquisition aligns with Namsa’s strategy to broaden its service capabilities for medtech manufacturers globally.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This move adds Labcorp’s US portfolio of biocompatibility, microbiological, analytical testing, and preclinical research services to Namsa’s existing operations.
Namsa is a global provider of preclinical and clinical services, medical device testing, and regulatory consulting from facilities in the US, Asia, and Europe.
Following the acquisition, future testing and preclinical projects for former Labcorp early development medical device clients will be handled at Namsa’s sites in California, Georgia, Minnesota and Ohio.
Namsa CEO Brian Smith said: “This acquisition is a perfect fit for Namsa – we serve 3,000+ medtech companies globally in these specific areas of testing and preclinical research.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“I am confident we will be able to provide Labcorp’s medical device clients with a smooth transition, combined with the same high level of expertise and customer service current Namsa clients have come to expect from us.”
Labcorp’s early development research laboratories EVP and president Brian Caveney said: “The sale of our early development medical device testing business to Namsa allows Labcorp to focus on core areas of preclinical drug development and chemical testing. We are pleased Namsa will continue providing leading expertise to clients in this space and are committed to a seamless transition.”
This marks Namsa’s tenth acquisition since joining ARCHIMED in 2020.
In January 2025, Namsa acquired the US-based medical device testing operations of WuXi AppTec to strengthen its medtech clinical research testing capabilities.
